Lrrk2 Signaling Pathway In Parkinson'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Leucine-Rich Repeat Kinase 2 (LRRK2) is a large multidomain protein kinase that has emerged as one of the most significant therapeutic targets in Parkinson's Disease (PD). Pathogenic mutations in the LRRK2 gene are the most common known genetic cause of familial PD, and the protein's role in cellular signaling makes it a promising intervention point for disease modification.
LRRK2 is a 2527-amino acid protein containing multiple functional domains:
LRRK2 is widely expressed in the brain, with highest levels in:
The protein localizes to multiple cellular compartments:
LRRK2 autophosphorylates on multiple serine/threonine residues, particularly:
The kinase (kinase activation activity is regulated by:
| Mutation | Domain | Effect on Kinase Activity | Population Frequency |
|---|---|---|---|
| G2019S | Kinase | Increased activity | ~5% familial PD, ~1% sporadic PD |
| R1441C/G/H | ROC | Decreased GTPase activity | ~3% familial PD |
| N1437H | ROC | Altered GTPase activity | Rare |
| Y1699C | COR | Decreased GTPase activity | Rare |
| R1441H | ROC | Loss of function | Rare |
The G2019S mutation accounts for approximately:
The mutation increases LRRK2 kinase activity by approximately 2-3 fold, leading to enhanced downstream signaling and cellular dysfunction.
LRRK2 phosphorylates a subset of Rab GTPases, including:
This affects:
LRRK2 interacts with the mTOR pathway, affecting:
LRRK2 mutations affect Wnt/β-catenin signaling, impacting:
LRRK2 pathogenic mutations lead to dopaminergic neuron death through multiple mechanisms:
LRRK2 is expressed in microglia and immune cells:
LRRK2 mutations affect:
Multiple LRRK2 inhibitors have been developed and tested in clinical trials:
| Drug | Company | Development Stage | Notes |
|---|---|---|---|
| DNL151 | Denali/Biogen | Phase 1/2 | CNS-penetrant |
| BIIB122 (DNL151) | Biogen | Phase 2b | LRRK2 inhibitor |
| LRRK2-IN-1 | Various | Preclinical | Tool compound |
| MLi-2 | Merck | Preclinical | Potent inhibitor |
The study of Lrrk2 Signaling Pathway In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. Science. 2018;361(6405):904-906.
Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci. 2023;24(8):481-495.
Satake W, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41(12):1303-1307.
Zimprich A, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601-607.
Rideout HJ, charting LRRK2 inhibitor clinical development. Nat Rev Drug Discov. 2023.
Liu Z, et al. LRRK2 phosphorylates Rab GTPases and modulates lysosomal function. Nat Neurosci. 2024.
Chen Z, et al. Pathogenic LRRK2 variants induce dopaminergic neurodegeneration through altered autophagy. Brain. 2025.
Tolosa E, et al. LRRK2 in Parkinson disease: challenges and opportunities. Nat Rev Neurol. 2024.
Wallings R, et al. LRRK2 and the immune system. J Parkinsons Dis. 2023.
Saez-Atienzar S, et al. The LRRK2 inhibitor DNL151: results from first-in-human study. Mov Disord. 2024.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 31%